Cited by 1,415Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Open access

Rizvi, Naiyer A, Mazières, Julien, Planchard, David, Stinchcombe, Thomas E, Dy, Grace K, Antonia, Scott J, Horn, Leora, Lena, Hervé, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A, Campos, Luis T, Gandara, David R, Levy, Benjamin P, Nair, Suresh G, Zalcman, Gérard, Wolf, Jürgen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M, Harbison, Christopher T, Baudelet, Christine, Lestini, Brian J, Ramalingam, Suresh S·2015·The Lancet Oncology

DOI 10.1016/s1470-2045(15)70054-9PMC PMC5726228

Open this paper in CoChat — free account

Abstract

Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)70054-9

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation

Show all 36 references

Sorted by citations

Items 801–900 of 1,000

Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma
Zhao, C. Y., Hwang, S. J. E., Anforth, R. M., Carlos, G., Chou, S., Carlino, M. S., & Fernández‐Peñas, P. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000237 · Cited by 18
Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors
Anderson, D., Beecher, G., Nathoo, N., Smylie, M., McCombe, J. A., Walker, J. W. T., & Jassal, R. (2018) · Neuro-Oncology Practice · doi:10.1093/nop/npy039 · Cited by 18
Hepatic Injury Induced by a Single Dose of Nivolumab – a Case Report and Literature Review
Kopecký, J., Kubeček, O., Geryk, T., Podhola, M., Žiaran, M., Priester, P., Hanišová, M., & Bořilová, S. (2019) · Klinicka onkologie · doi:10.14735/amko2019133 · Cited by 18
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology☆
Breccia, M., Carver, J. R., Szmit, S., Jurczak, W. J., Salvatorelli, E., & Minotti, G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.005 · Cited by 18
The Clinical Features, Prognostic Significance, and Immune Heterogeneity of CD37 in Diffuse Glioma
Yan, X., Zhou, Q., Zhu, H., Liu, W., Xu, H., Yin, W., Zhao, M., Jiang, X., & Ren, C. (2021) · iScience · doi:10.1016/j.isci.2021.103249 · Cited by 18
TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
Khanolkar, R. C., Zhang, C., Al-Fatyan, F., Lawson, L., Depasquale, I., Meredith, F. M., Muller, F., Nicolson, M. C., Dahal, L. N., Eid, R. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763877 · Cited by 18
Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
Kim, S. Y., Kim, T., Park, C. K., Yoon, H.-K., Jo, Y., Kim, H. R., Woo, I. S., & Kim, T. J. (2022) · Cancers · doi:10.3390/cancers14133138 · Cited by 18
Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study
Liu, K., Qin, Z., Ge, Y., Bian, A., Xu, X., Wu, B., Xing, C., & Mao, H. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04437-9 · Cited by 18
Potential biomarkers for immunotherapy in non-small-cell lung cancer
Wang, X., Qiao, Z.-Y., Aramini, B., Lin, D. X., Li, X., & Fan, J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10074-y · Cited by 18
Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials
Fountzilas, E., Vo, H. H., Mueller, P. J., Kurzrock, R., & Tsimberidou, A. M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.015 · Cited by 18
Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
Wang, F., Xia, T., Li, Z., Gao, X., & Fang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1213297 · Cited by 19
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?
Spagnolo, C. C., Pepe, F., Ciappina, G., Nucera, F., Ruggeri, P., Squeri, A., Speranza, D., Silvestris, N., Malapelle, U., & Santarpía, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104332 · Cited by 18
Skin Reactions to Immune Checkpoint Inhibitors
Patel, A. B., & Pacha, O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_9 · Cited by 18
The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials
Zhao, B., Zhang, W., Yu, D., Xu, J., & Wei, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1387 · Cited by 18
Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature
Vittorio, A. F., Sharma, R. K., Siejka, D. A., Bhattarai, K., & Hardikar, A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.010 · Cited by 18
On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
Ward, F. J., Dahal, L. N., & Eid, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02182 · Cited by 18
Cell‐blocks are suitable material for programmed cell death ligand‐1 immunohistochemistry: Comparison of cell‐blocks and matched surgical resection specimens in lung cancer
Pak, M. G., & Roh, M. S. (2019) · Cytopathology · doi:10.1111/cyt.12743 · Cited by 18
Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab
Hu, J., Li, Y., Chen, X., Luo, C., & Zuo, X. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13217 · Cited by 18
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Dudzińska, M., Szczyrek, M., Wojas‐Krawczyk, K., Świrska, J., Chmielewska, I., & Zwolak, A. (2020) · Cancers · doi:10.3390/cancers12082314 · Cited by 19
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis
Giustozzi, M., Becattini, C., Roila, F., Agnelli, G., & Mandalà, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102280 · Cited by 19
OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer
Lao, J., Cao, C., Niu, X., Deng, S., Ming, S., Liang, S., Shang, Y., Yuan, Y., Shi, X., Liang, Z., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108813 · Cited by 18
The side effects of immune checkpoint inhibitor therapy on the endocrine system
Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18
Expert opinion on immunotherapy induced diabetes
Smati, S., Buffier, P., Bouillet, B., Archambeaud, F., Vergès, B. L., & Cariou, B. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.006 · Cited by 18
A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine
Kikuchi, H., Sakuraba, H., Akemoto, Y., Murai, Y., Fukutoku, Y., Asari, T., Tatsuta, T., Hasui, K., Hiraga, H., Sawaya, M., et al. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1580477 · Cited by 18
Skin Reactions to Immune Checkpoint Inhibitors
Patel, A. B., & Pacha, O. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_5 · Cited by 18
Nivolumab for advanced squamous cell lung cancer: what are the next steps?
de Mello, R. A., Pousa, I. D., & Pereira, D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70074-4 · Cited by 17
Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer
Dermarkarian, C. R., Patel, N. A., Villegas, V. M., & Harbour, J. W. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100691 · Cited by 17
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives
O'Kane, G. M., & Leighl, N. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.09.05 · Cited by 18
Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review
Michalarea, V., Fontana, E., Garces, A. I., Williams, A., Smyth, E. C., Picchia, S., Rao, S., Chau, I., Cunningham, D., & Bali, M. A. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.01.008 · Cited by 17
Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance
Lin, D., Wang, Y., Zhou, Z., & Lin, Z. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.02.212 · Cited by 17
Early response of bone metastases can predict tumor response in patients with non‑small‑cell lung cancer with bone metastases in the treatment with nivolumab
Nakata, E., Sugihara, S., Sugawara, Y., Kozuki, T., Harada, D., Nogami, N., Nakahara, R., Furumatsu, T., Tetsunaga, T., Kunisada, T., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11856 · Cited by 17
Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing
Liang, Y., Tsai, J., Cheng, Y., Chan, K.-Y., Hsu, W.-L., Lee, C.-C., Chen, K., & Yeh, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-88648-z · Cited by 17
Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells
Takaku, S., Shimizu, M., & Takahashi, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.5937 · Cited by 17
Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions
Yan, Y., Zheng, Y., Ming, P., Deng, X.-X., Ge, W., & Wu, Y.-G. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely029 · Cited by 16
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
Fessenden, T. B., Stopfer, L. E., Chatterjee, F., Zulueta, J., Mesfin, J. M., Dumit, T. C., Reijers, I. L. M., Hoefsmit, E. P., Blank, C. U., White, F. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004159 · Cited by 16
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites
Martin, A. L., Powell, C. D., Nagy, M. Z., Innamarato, P., Powers, J. J., Nichols, D. A., Anadon, C. M., Chaurio, R. A., Kim, S., Wang, M.-H., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03325-y · Cited by 16
Self-citation
Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer
Li, E., Xu, J., Chen, Q., Zhang, X., Xu, X., & Liang, T. (2023) · Immunotherapy · doi:10.2217/imt-2021-0075 · Cited by 16
m6A‐ and immune‐related lncRNA signature confers robust predictive power for immune efficacy in lung squamous cell carcinoma
Ding, Z., Liu, Y., Huang, Q., Cheng, C., Song, L., Zhang, C., Cui, X., Wang, Y., Han, Y., & Zhang, H. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20220083 · Cited by 16
Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
Zhuansun, Y., Huang, F., Du, Y., Lin, L., Chen, R., & Li, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.104 · Cited by 16
The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer
Wong, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00033 · Cited by 16
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
Aggarwal, C., & Borghaei, H. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0345 · Cited by 16
Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer
El-Refai, S. M., Brown, J. D., Black, E. P., & Talbert, J. (2017) · Cancer Informatics · doi:10.1177/1176935117712520 · Cited by 16
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy
Yan, X., Wang, L., Zhang, R., Pu, X., Wu, S., Yu, L., Meraz, I. M., Zhang, X., Wang, J., Gibbons, D. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1376156 · Cited by 16
Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
Kwack, W. G., Shin, S. Y., & Lee, S. H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s272013 · Cited by 16
Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
Yang, Q., Wu, D., Wang, J., Ba, L., Tian, C., Liu, Y., Hu, Y., & Liu, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-92115-0 · Cited by 16
Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
Chmielewska, I., Dudzińska, M., Szczyrek, M., Świrska, J., Wojas‐Krawczyk, K., & Zwolak, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257484 · Cited by 16
Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis
Shea, M., Rangachari, D., Hallowell, R. W., Hollie, N. I., Costa, D. B., & VanderLaan, P. A. (2018) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2018.02.004 · Cited by 16
Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients
Zarrabi, K. K., & Wu, S. (2018) · Oncology · doi:10.1159/000486679 · Cited by 16
Expert opinions on adrenal complications in immunotherapy
Haissaguerre, M., Hescot, S., Bertherat, J. Y., & Chabre, O. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.002 · Cited by 16
Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28
Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., Tumino, N., Pietra, G., Mingari, M. C., & Moretta, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15081 · Cited by 17
Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
Sun, Y., Shao, C., Li, S., Xu, Y., Xu, K. L., Zhang, Y., Huang, H. F., Wang, M., & Xu, Z. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13380 · Cited by 16
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Zhou, F., & Zhou, C. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0036-4 · Cited by 17
Emerging drugs for squamous cell lung cancer
Cheng, H., Shcherba, M., Kandavelou, K., Liang, Y., Liu, H., & Perez-Soler, R. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1001365 · Cited by 15
Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab
Agrawal, S., Waxman, I. M., Lambert, A., Roy, A., & Darbenzio, R. B. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2980-3 · Cited by 15
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Soo, R. A., Ang, Y. L. E., & Lim, J. S. J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s84356 · Cited by 15
Immune Checkpoint Therapy in Non–Small Cell Lung Cancer
Marrone, K. A., & Brahmer, J. R. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000178 · Cited by 15
Nivolumab-induced vitiligo successfully treated with narrowband UVB phototherapy
Miyagawa, T., Kadono, T., Masui, Y., Yamada, D., Saigusa, R., Numajiri, H., Omatsu, J., Asano, Y., & Sato, S. (2017) · European Journal of Dermatology · doi:10.1684/ejd.2017.3096 · Cited by 15
Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
Pignata, M., CHOUAID, C., Lay, K. L., Luciani, L., McConnachie, C. C., Gordon, J., & Roze, S. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s136657 · Cited by 15
Self-citation
Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
Oliveira, L. J. D. C., Gongora, A. B. L., Barbosa, F. D. G., dos Anjos, C. H., & Munhoz, R. R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0444-5 · Cited by 15
Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
Wang, H., Zhao, S., Zhang, X., Jia, K., Deng, J., Zhou, C., & He, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214231 · Cited by 15
Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab
Okamoto, I., Sato, H., & Tsukahara, K. (2020) · Auris Nasus Larynx · doi:10.1016/j.anl.2020.04.001 · Cited by 15
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
Amrein, M. A., Bührer, E. D., Amrein, M. L., Li, Q., Rothschild, S. I., Riether, C., Jaggi, R. B., Savic-Prince, S., Bubendorf, L., Gautschi, O. P., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02688-4 · Cited by 15
A rare case of immunotherapy-induced cholangitis and gastritis
Fujii, M., Ozato, T., Mizukawa, S., Nasu, J., Kawai, H., Fujioka, S., Yoshioka, M., Shiode, J., & Yamamoto, K. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01218-0 · Cited by 15
Radiological imaging features of the salivary glands in xerostomia induced by an immune checkpoint inhibitor
Katsura, K., Funayama, S., Ito, K., Nohno, K., Kaneko, N., Takamura, M., Soga, M., Kobayashi, T., & Hayashi, T. (2020) · Oral Radiology · doi:10.1007/s11282-020-00480-9 · Cited by 15
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
Heudobler, D., Schulz, C. K. J., Fischer, J. R., Staib, P., Wehler, T., Südhoff, T., Schichtl, T., Wilke, J., Hahn, J., Lüke, F., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.599598 · Cited by 15
Perspectives of future lung toxicology studies using human pluripotent stem cells
Masui, A., Hirai, T., & Gotoh, S. (2022) · Archives of Toxicology · doi:10.1007/s00204-021-03188-9 · Cited by 16
Study of the occupational health risk of radon exposure in underground workers in a mine
Liu, G., Niu, L. M., Cao, X. B., Liu, Y. Y., Wu, X. Q., Zhang, X., Zhang, R., & Li, Y. (2022) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2022.05.018 · Cited by 15
A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma in vivo
Li, L., Zhou, Y., Zhang, Y., Hu, H., Mao, H., & Selaru, F. M. (2023) · iScience · doi:10.1016/j.isci.2023.106095 · Cited by 15
Into the Clinic With Nivolumab and Pembrolizumab
Shu, C. A., & Rizvi, N. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0099 · Cited by 15
Self-citation
An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers
Wong, C. Y., & Ma, B. B. Y. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1223047 · Cited by 15
Durvalumab in Non-Small-Cell Lung Cancer Patients: Current Developments
Mezquita, L., & Planchard, D. (2017) · Future Oncology · doi:10.2217/fon-2017-0373 · Cited by 15
Self-citation
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
Jaafar, J., Fernández, E., Alwan, H., & Philippé, J. (2018) · Endocrine Connections · doi:10.1530/ec-18-0079 · Cited by 16
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
Pu, X., Zhang, R., Wang, L., Chen, Y., Xu, Y., Pataer, A., Meraz, I. M., Zhang, X., Wu, S., Wu, L., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1704-3 · Cited by 15
Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?
Al‐Mansour, Z., Pang, L., & Bathini, V. G. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0619-2 · Cited by 15
Asthma management by an inpatient asthma care team.
Ebbinghaus, S., & Bahrainwala, A. H. (2003) · PubMed · Cited by 15
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience
Vitale, G., Lamberti, G., Comito, F., Nunno, V. D., Massari, F., Morelli, M. C., Ardizzoni, A., & Gelsomino, F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762562 · Cited by 14
Atypical Patterns of Response and Progression in the Era of Immunotherapy Combinations
Ferrara, R., & Matos, I. G. (2020) · Future Oncology · doi:10.2217/fon-2020-0186 · Cited by 14
Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Reese, S. W., Cone, E. B., Marchese, M., Garcia, B. D., Chou, W. H., Ayub, A., Kilbridge, K. L., Weinhouse, G. L., & Trinh, Q. (2021) · Lung · doi:10.1007/s00408-021-00425-x · Cited by 14
CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1
Shan, H.-S., Zhang, X., Zhang, X., Wei, Y., Meng, L., Li, J., Zhang, Z., Ma, L., & Xiao, Y. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00696-0 · Cited by 14
Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)
Casili, G., Scuderi, S. A., Lanza, M., Filippone, A., Mannino, D., Giuffrida, R., Colarossi, C., Mare, M., Capra, A. P., Gaetano, F. D., et al. (2023) · Cancers · doi:10.3390/cancers15102796 · Cited by 14
Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial
Pan, H., Yu, M., Tang, X., Mao, X., Liu, M., Zhang, K., Qian, C., Ji, W., Xie, H., Qiu, W., et al. (2024) · Med · doi:10.1016/j.medj.2024.01.015 · Cited by 14
Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis
Zhang, X., Wu, M., Chen, J., Zheng, K., Du, H., Li, B., Gu, Y., & Jiang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30809 · Cited by 14
Targeting the immune system to treat lung cancer: rationale and clinical experience
Guibert, N. M., Delaunay, M., & Mazières, J. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815578349 · Cited by 14
Self-citation
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer
Cho, J. H., Öezkan, F., Koenig, M. J., Otterson, G. A., Herman, J. G., & He, K. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0110-5 · Cited by 14
Self-citation
Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy
Geraci, E., & Chablani, L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103009 · Cited by 14
Resistance to Therapy
Rivera, G. A., & Wakelee, H. A. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_9 · Cited by 14
Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review
Zhang, Z., Chen, Y., Ma, M., Hao, J., Ding, R., Han, L., Zou, J., Zhang, L., Meng, Q., Qu, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19089 · Cited by 14
Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
Jiang, Q., Xie, M., He, M., Yan, F., Zhang, X., & Yu, S. (2017) · Oncotarget · doi:10.18632/oncotarget.23584 · Cited by 14
Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
Sughayer, M. A., Alnaimy, F., Alsughayer, A. M., & Qamhia, N. (2018) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000671 · Cited by 14
Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer
Doumas, S., Foukas, P. G., Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104477 · Cited by 14
Immune‑related genes and gene sets for predicting the response to anti‑programmed death 1 therapy in patients with primary or metastatic non‑small cell lung cancer
Chen, B., Yang, M., Li, K., Li, J., Xu, L., Xu, F., Xu, Y., Ren, D., Zhang, J., & Liu, L.-Y. D. (2021) · Oncology Letters · doi:10.3892/ol.2021.12801 · Cited by 14
Immunological Aspects of Malignant Gliomas
Cohen‐Inbar, O., & Zaaroor, M. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.34 · Cited by 14
Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer
Rebuzzi, S. E., Leonetti, A., Tiseo, M., & Facchinetti, F. (2019) · Immunotherapy · doi:10.2217/imt-2019-0107 · Cited by 14
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 13
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Malik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 14
Synthetic lethal CRISPR screen identifies a cancer cell-intrinsic role of PD-L1 in regulation of vulnerability to ferroptosis
Feng, Y.-Y.-F., Li, Y., Liu, H., Xu, R., Liu, Y.-T., Zhang, W., Yang, H., & Chen, G. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114477 · Cited by 13
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Horaguchi, S., Nakahara, Y., Igarashi, Y., Kouro, T., Wei, F., Murotani, K., Udagawa, S., Higashijima, N., Matsuo, N., Murakami, S., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081831 · Cited by 14
Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets
Zhao, Y., Qin, C., Chen, L., Li, Z., Zhao, B., Li, T., Zhang, X., & Wang, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189183 · Cited by 14
Nanomedicines modulate the tumor immune microenvironment for cancer therapy
Chao, P., Chan, V., & Li, S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2412245 · Cited by 13

Authors: Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Centre Hospitalier Universitaire de Toulouse (FR)
Institut Gustave Roussy (FR)
University of North Carolina at Chapel Hill (US)
Roswell Park Comprehensive Cancer Center (US)
Moffitt Cancer Center (US)
Vanderbilt University (US)
Azienda Ospedaliera S.Maria (IT)
Hôpital Civil, Strasbourg (FR)
The Ohio State University Wexner Medical Center (US)
UC Davis Comprehensive Cancer Center (US)
Mount Sinai Beth Israel (US)
Lehigh Valley Hospital (US)
Centre Hospitalier Universitaire de Caen Normandie (FR)
University Hospital Cologne (DE)
Hospices Civils de Lyon (FR)
Ospedale di Livorno (IT)
University Hospitals of Cleveland (US)
Providence Portland Medical Center (US)
German Center for Lung Research (DE)
Princeton University (US)
Emory University (US)
Corresponding author: Rizvi, Naiyer A
ORCID: Rizvi, Naiyer A
Mazières, Julien
Planchard, David
Stinchcombe, Thomas E
Dy, Grace K
Antonia, Scott J
Horn, Leora
Mennecier, Bertrand
Otterson, Gregory A
Campos, Luis T
Gandara, David R
Levy, Benjamin P
Nair, Suresh G
Zalcman, Gérard
Wolf, Jürgen
Cappuzzo, Federico
Chouaid, Christos
Dowlati, Afshin
Sanborn, Rachel
Huber, Rudolf M
Ramalingam, Suresh S
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2015-03
Volume: 16
Issue: 3
Pages: 257-265
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(15)70054-9
PMC: PMC5726228
OpenAlex: W2106511606
Cited by: 1,415
References: 36
Citations by year: 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
FWCI: 108.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P30CA076292)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
MeSH terms: Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks